| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 42.2 | 38.3 | 39.1 |
| Other income | 1.8 | 1.2 | 1.0 |
| Total income | 44.0 | 39.5 | 40.1 |
| Profit before exceptional items & tax | 2.6 | 1.8 | 3.1 |
| Exceptional items | 0.0 | 0.0 | -1.8 |
| Profit before tax | 2.6 | 1.8 | 1.3 |
| Net profit | 2.7 | 1.8 | 1.3 |
| Operating margin | 5.9% | 4.6% | 3.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +107.70% |
|---|---|
| Net profit, quarter on quarter | +50.00% |
| Revenue, year on year | +7.90% |
Source
Read the filing ↗
NSE results filing, NSE: BAFNAPH. Figures extracted from the filing.
Bafna Pharmaceuticals Ltd: key numbers
- Share price
- ₹350.05
- Market cap
- ₹828.1 Cr
- Revenue (annual)
- ₹150.6 Cr
- Net profit (annual)
- ₹11.10 Cr
- P/E (TTM)
- 106.4×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 9.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bafna Pharmaceuticals Ltd
All →
15:03 IST
BSE
Annual General Meeting
Bafna Pharmaceuticals Annual General Meeting
Bafna Pharmaceuticals' 31st AGM held on September 11, 2026 approved adoption of audited financials, a director re-appointment, and cost auditor ratification. No specific monetary transaction was transacted.
17:51 IST
BSE
Financial Results
Bafna Pharmaceuticals Q1 FY27 Results: Net Profit ₹0.1 Cr, Down 97.1% YoY
Bafna Pharmaceuticals Ltd reported revenue from operations of ₹26.6 Cr (-23.1% YoY) and net profit of ₹0.1 Cr (-97.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.1 Cr · -97.1% YoY